Second Multiple Myeloma Antibody Approved – Empliciti | Cancer Biology
NDC 0003-4522 Empliciti Elotuzumab
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma | Oncology Practice Management
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma | SpringerLink
Mechanism of Action | EMPLICITI® (elotuzumab)
BMS, AbbVie's Empliciti flunks trial in first-line multiple myeloma - PMLiVE
First and only antibody for Multiple Myeloma approved in EU
Precision Medicine Empliciti Improves Survival of Recurrent Multiple Myeloma - CancerConnect
Elotuzumab | New Drug Approvals
Empliciti efficacy benefits shown in extended follow-up data
![Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract]](https://www.thno.org/v11/p3580/toc.jpg "Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract]")
Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy [Abstract]
FDA Approves EMPLICITI® Combination for Relapsed Refractory Multiple Myeloma – OncoPrescribe
Trial Design | POMALYST® (pomalidomide) + dex + EMPLICITI® (elotuzumab)
Mechanisms of Action and Clinical Development of Elotuzumab - Ritchie - 2018 - Clinical and Translational Science - Wiley Online Library
Empliciti - FDA prescribing information, side effects and uses
Elotuzumab (Empliciti) Drug Info
POMALYST® (pomalidomide) Mechanism of Action
BMS and AbbVie's myeloma drug Empliciti gains approval -
Mechanism of Action | EMPLICITI® (elotuzumab)
Bristol Myers Squibb - Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies
European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma | Business Wire
Elotuzumab (Empliciti) - Oncology Nurse Advisor
BMS and AbbVie's myeloma drug Empliciti gains approval -
Elotuzumab: Uses, Interactions, Mechanism of Action | DrugBank Online
